Dividend PayoutDividend payout increased by 10ppts to 51% in 2024, with the higher payout expected to continue given solid financial position, translating into an attractive yield of 7%+.
Product PenetrationFurther penetration of uremic clearance granules in hospitals is expected to drive EPS growth, with significant penetration already achieved in top-tier hospitals.
Sales GrowthPotential introduction of new drugs, with focus areas being identified, could be a catalyst and drive sales growth ahead.